Peroxide-driven cytochrome P450 oxygenase variants
The invention relates to novel variants of cytochrome P450 oxygenases. These variants have an improved ability to use peroxide as an oxygen donor as compared to the corresponding wild-type enzyme. These variants also have an improved thermostability as compared to the cytochrome P450 BM-3 F87A mutant. Preferred variants include cytochrome P450 BM-3 heme domain mutants having I58V, F87A, H100R, F107L, A135S, M145A/V, N239H, S274T, L324I, I366V, K434E, E442K, and/or V446I amino acid substitutions.
1. An isolated nucleic acid encoding a variant of a parent cytochrome P450 oxygenase comprising the amino acid sequence of SEQ ID NO:13, wherein the variant consists of a first mutation at amino acid residue F87 of SEQ ID NO:13 and at least one second mutation selected from the group consisting of K9, I58, E93, H100, F107, K113, A135, M145, N186, D217, M237, N239, S274, L324, I366, K434, E442, and V446, of SEQ ID NO:13 and wherein the variant has an enhanced capacity of using peroxide as an oxygen donor compared to the parent.
2. The isolated nucleic acid of claim 1 , wherein the parent is wild type cytochrome P450 BM-3.
3. The isolated nucleic acid of claim 1 , wherein the first mutation is F87A or F87S mutation.
4. The isolated nucleic acid of claim 1 , wherein the second mutation is selected from the group consisting of K9I , I58V, E93G, H100R, F107L, K113E, A135S, M145A, M145V, N186S, D217V, M237L, N239H, S274T, L324I, I366V, K434E, E442K, and V446I.
5. The isolated nucleic acid of claim 4 , wherein the enhanced use of peroxide is selected from the group consisting of improved peroxide shunt activity, improved hydroxylation of substrate in the absence of a cofactor, improved hydroxylation of substrate at a lower concentration of peroxide, and improved rate of hydroxylation of substrate at a given concentration of peroxide.
6. The isolated nucleic acid of claim 1 , wherein the variant consists of amino acid mutations at amino acid residues corresponding to amino acid residues F87, H100, M145, M237, S274, and K434 of SEQ NO:13.
7. The isolated nucleic acid of claim 6 , wherein the amino acid mutations are F87A, H100R, M145V, M237L, S274T, and K434E.
8. The isolated nucleic acid of claim 5 , wherein the variant consists of amino acid mutations corresponding to the amino acid mutations I58V, F87A, H100R, F107L, A135S, M145A, N239H, S274T, K434E, and V446I of SEQ ID NO:13.
9. The isolated nucleic acid of claim 5 , wherein the variant consists of amino acid mutations corresponding to the amino acid mutations I58V, F87A, H100R, F107L, A135S, M145A, N239H, S274T, L324I, I366V, K434E, E442K, and V446I of SEQ ID NO :13.
10. The isolated nucleic acid of claim 1 , wherein the peroxide is selected from hydrogen peroxide, t-butyl hydroperoxide, and cumene hydroperoxide.
11. The isolated nucleic acid of claim 1 , wherein the second mutation is selected from the group consisting of H100, M145, M237, S274, and K434 of SEQ ID NO:13.
12. The isolated nucleic acid of claim 11 , wherein the second mutation is selected from the group consisting of H100R, M145A, M145V, M237L, S274T, and K434E.
13. The isolated nucleic acid of claim 12 , wherein the first mutation is F87A or F87S.
14. The isolated nucleic acid of claim 3 , wherein the variant has a lesser cytotoxicity than the parent.
15. The isolated nucleic acid of claim 1 , wherein the variant has a higher thermostability than the parent.
16. The isolated nucleic acid of claim 15 , wherein the variant consists of a mutation at an amino acid residue corresponding to an amino acid residue selected from M145, L324, I366, and E442 of SEQ ID NO:13.
17. The isolated nucleic acid of claim 16 , wherein the mutation is selected from M145A, L324I, I366V, and E442K.
18. The isolated nucleic acid of claim 15 , wherein the variant consists of amino acid mutations corresponding to the amino acid mutations M145A, L324I, I366V, and E442K of SEQ ID 13 .
19. An isolated nucleic acid encoding a variant of a wild-type parent Bacillus megaterium monooxygenase-3 (BM-3) comprising the amino acid sequence of SEQ ID NO:2, wherein the variant consist of mutations in heme domain amino acid sequences of BM-3 and wherein the variant heme domain amino acid sequences consist of a first mutation at residue F87 of SEQ ID NO:13 and one or more second mutations selected from the group consisting of K9, I58, E93, H100, F107, K113, A135, M145, N186, D217, M237, N239, S274, L324, I366, K434, E442, and V446 of SEQ ID NO:13, wherein the variant has an enhanced capacity of using peroxide as an oxygen donor compared to the parent.
20. The isolated nucleic acid of claim 19 , wherein the enhanced use of peroxide is selected from the group consisting of improved peroxide shunt activity, improved hydroxylation of substrate in the absence of a cofactor, improved hydroxylation of substrate at a lower concentration of peroxide, and improved rate of hydroxylation of substrate at a given concentration of peroxide.
21. The isolated nucleic acid of claim 19 , wherein the first mutation is selected from F87A and F87S, and the at least one second mutation is selected from K9I, I58V, E93G, H100R, F107L, K113E, A135S, M145A, M145V, N186S, D217V, M237L, N239H, E244G, S274T, L324I, I366V, K434E, E442K, and V446I.
22. The isolated nucleic acid of claim 19 , wherein the variant consists of amino acid mutations at amino acid residues corresponding to amino acid residues F87, H100, M145, M237, S274, and K434 of SEQ NO:13.
23. The isolated nucleic acid of claim 22 , wherein the amino acid mutations are F87A, H100R, M145V, M237L, S274T, and K434E.
24. The isolated nucleic acid of claim 19 , wherein the variant consists of two second mutations selected from the group consisting of K9, I58, E93, H100, F107, K113, A135, M145, N186, D217, M237, N239, S274, L324, I366, K434, E442, and V446.
25. The isolated nucleic acid of claim 24 , wherein one second mutation is selected from the group consisting of H 100, M145, M237, S274, and K434 of SEQ ID NO:13.
26. The isolated nucleic acid of claim 19 , wherein the variant has a higher thermostability than the parent.
27. The isolated nucleic acid of claim 26 , wherein the variant consists of a mutation at an amino acid residue corresponding to an amino acid residue selected from M145, L324, I366, and E442 of SEQ ID NO:13.
28. The isolated nucleic acid of claim 27 , wherein the mutation is selected from M145A, L321I, I366V, and E442K.
29. An isolated nucleic acid encoding a variant of a wild-type parent Bacillus megaterium monooxygenase-3 (BM-3) enzyme comprising the amino acid sequence of SEQ ID NO:2, wherein the variant consists of mutations in heme domain amino acid sequences, and wherein the variant has an enhanced capacity of using peroxide as an oxygen donor compared to the parent, wherein the variant heme domain amino acid sequences consist of a first mutation at residue F87 of SEQ ID NO:13, and one or more second mutations selected from the group consisting of H100, M145, M237, S274, and K434 of SEQ ID NO:13.
30. The isolated nucleic acid of claim 29 , wherein the enhanced use of peroxide is selected from the group consisting of improved peroxide shunt activity, improved hydroxylation of substrate in the absence of a cofactor, improved hydroxylation of substrate at a lower concentration of peroxide, and improved rate of hydroxylation of substrate at a given concentration of peroxide.
31. The isolated nucleic acid of claim 29 , wherein the first mutation is selected from F87A and F87S, and the one or more second mutations are selected from H100R, M145A, M145V, M237L, S274T, and K434E.
32. An isolated nucleic acid encoding a variant of an isolated heme domain of a wild-type parent Bacillus megaterium monooxygenase-3 (BM-3) cytochrome P450 enzyme comprising the amino acid sequence of SEQ ID NO:13, wherein the variant heme domain consists of a first mutation at amino acid F87 of SEQ ID NO:13, and one or more second mutations selected from the group consisting of K9, I58, E93, H100, F107, K113, A135, M145, N186, D217, M237, N239, S274, L324, I366, K434, E442, and V446 of SEQ ID NO:13.
33. The isolated nucleic acid of claim 32 , wherein the one or more second mutations is selected from the group consisting of K9I, I58V, E93G, H100R, F107L, K113E, A135S, M145A, M145V, N186S, D217V, M237L, N239H, S274T, L324I, I366V, K434E, E442K, and V446I.
34. The isolated nucleic acid of claim 32 , wherein the one or more second mutations is at an amino acid residue of selected from H100, M145, M237, S274, and K434 of SEQ ID NO :13.
35. The isolated nucleic acid of claim 34 , wherein the first mutation is selected from F87A and F87S, and the second mutation is selected from H100R, M145A, M145V, M237L, S274T, and K434E.
36. An isolated nucleic acid encoding a variant of a wild-type cytochrome P450 Bacillus megaterium monooxygenase-3 (BM-3) heme domain comprising the amino acid sequence of SEQ ID NO:13, wherein the variant has an enhanced capacity of using peroxide as an oxygen donor compared to the parent, and wherein the variant consists of a first mutation corresponding to amino acid residue F87 of SEQ ID NO:13 and one or more second mutations at an amino acid residue selected from H100, M145, M237, S274, and K434 of SEQ ID NO:13.
37. The isolated nucleic acid of claim 36 , wherein the first mutation is selected from F87A and FB7S.
38. The isolated nucleic acid of claim 37 , wherein the second mutation is selected from H100R, M145V, M145A, M237L, S274T, K434E, and combinations thereof.
39. The isolated nucleic acid of claim 36 , comprising mutations at residues F87, H100, M145, M237, S274, and K434.
40. The isolated nucleic acid of claim 38 , wherein the mutations are F87A, H100R, M145V, M237L, S274T, and K434E.
41. The isolated variant of claim 39 , wherein the variant has a higher thermostability than the wild-type heme domain.